Afraxis Raises $1.2M in Venture Funding

5/14/10Follow @bvbigelow

San Diego-based aFraxis, which has completed pre-clinical testing of a promising compound for treating fragile X syndrome, the most common cause of inherited mental impairment, has raised $1.2 million in a venture round targeting $6 million, according to a recent regulatory finding. San Diego’s Avalon Ventures already has invested about $6 million since the company was founded three years ago.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at or call (619) 669-8788 Follow @bvbigelow

By posting a comment, you agree to our terms and conditions.